RE: Directors talk19 Apr 2018 12:19
They did too small a trial, perhaps made some mistakes along the way (decision-wise) and the geographic split of patients maybe wasn't right. but heh ho... imm are only a small company (limited trial budget). Sell it to a big pharma, let them do it correctly, to skew the statistics in our favour, and let's get this drug on the market. for the patient's sake.
Petrol analogy
People tank 4 star, while others prefer 5 star.
Lupuzor may be the 4-star (less effective), but it doesn't have the adverse reactions of the 5-star drugs.
As a lupus patient, I'd rather refuel with the safer 4-star....